BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Advanced Therapies Wales - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://advancedtherapieswales.co.uk
X-WR-CALDESC:Events for Advanced Therapies Wales
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260826T160000
DTEND;TZID=Europe/London:20260826T163000
DTSTAMP:20260804T113642Z
CREATED:20260804T113642Z
LAST-MODIFIED:20260804T113642Z
UID:728-1787760000-1787761800@advancedtherapieswales.co.uk
SUMMARY:High-yield continuous lentiviral vector bioprocessing through perfusion intensification and integrated cold chain affinity capture
DESCRIPTION:Perfusion intensification\, cold harvest stabilization\, and inline affinity capture together can more than double lentiviral vector (LVV) recovery while removing steps from the process. This session presents a continuous LVV workflow that reached around 12 × 10⁶ viable cells/mL before transfection and delivered roughly 16-fold higher cumulative transduction units over 3 days through cold harvest handling. \nKeen Chung\, Technical Lead for Viral Vector Culture and Analytics at Repligen\, will show how coupling affinity capture directly to the perfusion permeate eliminates clarification and bulk harvest storage\, cutting hold times\, contamination risk\, and product loss. \nAttend this webinar to: \n\nApply a perfusion intensification approach that reached around 12 × 10⁶ viable cells/mL before transfection\, roughly 4-fold higher cell density\, to raise vector yield and cell-specific productivity\nQuantify how continuous cold harvest at 4°C delivered around 16-fold higher cumulative transduction units over 3 days\, informed by an LVV infectivity half-life of around 6 h at 37°C versus around 300h at 4°C\nSee how affinity capture coupled directly to the permeate enables continuous\, hold-free purification and removes clarification and bulk storage as separate unit operations\n\nCompare overall recovery against a conventional depth filtration and anion exchange chromatography route (around 25%)\, which the integrated process improved more than 2.5-fold \n  \nFind out more
URL:https://advancedtherapieswales.co.uk/event/high-yield-continuous-lentiviral-vector-bioprocessing-through-perfusion-intensification-and-integrated-cold-chain-affinity-capture/
LOCATION:Online
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://advancedtherapieswales.co.uk/wp-content/uploads/2026/08/Repligen-webinar-web.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260909T160000
DTEND;TZID=Europe/London:20260909T170000
DTSTAMP:20260804T114504Z
CREATED:20260804T114504Z
LAST-MODIFIED:20260804T114504Z
UID:731-1788969600-1788973200@advancedtherapieswales.co.uk
SUMMARY:Delivering confidence in precision medicine: strategies for potency\, safety\, and long-term success
DESCRIPTION:This webinar explores the scientific and analytical capabilities required to support precision medicine programs across advanced modalities such as cell and gene therapy\, and complex therapeutic areas\, including oncology and neurology. \nJoin an expert panel as they explore key considerations in potency assessment\, safety monitoring and evidence generation\, with a focus on building integrated strategies that support development from early research through long-term follow-up. \nRegister now to explore real-world perspectives on:  \n\nDefining and measuring clinically meaningful potency across CAR-T\, in vivo gene therapy\, and other CGT modalities\, and how potency strategy evolves from early development through regulatory submission\nDesigning safety monitoring programs that extend beyond clinical trials\, including long-term follow-up\, registries\, and modality-specific risks such as immunogenicity and insertional mutagenesis\nIntegrating analytical data\, clinical endpoints\, and real-world evidence into a cohesive evidence strategy that supports regulatory and payer expectations\n\nHow manufacturing consistency\, analytical controls\, and cross-functional alignment contribute to sustained program confidence post-approval. \n  \nFind our more here
URL:https://advancedtherapieswales.co.uk/event/delivering-confidence-in-precision-medicine-strategies-for-potency-safety-and-long-term-success/
LOCATION:Online
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://advancedtherapieswales.co.uk/wp-content/uploads/2026/08/Thermofisher-webinar-web.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260916T160000
DTEND;TZID=Europe/London:20260916T170000
DTSTAMP:20260804T115238Z
CREATED:20260804T115238Z
LAST-MODIFIED:20260804T115238Z
UID:734-1789574400-1789578000@advancedtherapieswales.co.uk
SUMMARY:Transitioning to serum-free T cell manufacturing: process considerations and cross-platform scale-up data
DESCRIPTION:Serum is one of the largest sources of variability in T cell manufacturing\, driving lot-to-lot inconsistency\, sourcing constraints\, and contamination risk. This data-led session shows you how a chemically defined\, serum-free workflow removes that dependency\, so you can build more reproducible processes from early development through clinical scale. \nChengkang Zhang will walk through experimental data on the impact of serum removal at each stage of manufacturing: improved lentiviral vector transduction efficiency\, robust T cell expansion in serum-free culture\, and clinical-scale performance across multiple platforms. You will see cross-platform results spanning T-flasks\, G-Rex\, Xuri\, and Cocoon systems\, plus practical evidence on how oxygen transfer and media exchange strategies shape expansion outcomes. \nAttend this webinar to: \n\nTake away a data-backed framework for evaluating and implementing serum-free T cell culture in your own workflows\nSee experimental data showing improved lentiviral vector transduction efficiency and consistent expansion after serum removal\nCompare cross-platform scale-up performance across T-flasks\, G-Rex\, Xuri\, and Cocoon systems\, from research through clinical manufacturing\nLearn the critical success factors that determine a successful transition\, including cell handling\, media management\, and dissolved oxygen control\n\nChengkang (CK) Zhang\, Associate Director\, R&D\, Lonza\, brings extensive experience in mammalian cell culture and chemically defined media development for cell therapy\, and is the inventor of several cell culture technology patents. \nFind out more
URL:https://advancedtherapieswales.co.uk/event/transitioning-to-serum-free-t-cell-manufacturing-process-considerations-and-cross-platform-scale-up-data/
LOCATION:Online
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://advancedtherapieswales.co.uk/wp-content/uploads/2026/08/Lonza-webinar-web.png
END:VEVENT
END:VCALENDAR